HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM)

CUSIP: 40434H203

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class
Equity / COM NEW
Total 13F shares
605,347
Share change
-1,689,763
Total reported value
$622,000
Price per share
$1.02
Number of holders
14
Value change
-$2,411,094
Number of buys
8
Number of sells
8

Quarterly Holders Quick Answers

What is CUSIP 40434H203?
CUSIP 40434H203 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM) as of Q2 2022

As of 30 Jun 2022, HTG MOLECULAR DIAGNOSTICS IN - COM NEW (HTGM) was held by 14 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 605,347 shares. The largest 10 holders included RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, BlackRock Inc., VANGUARD GROUP INC, TWO SIGMA SECURITIES, LLC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, CITIGROUP INC, STATE STREET CORP, and Virtu Financial LLC. This page lists 14 institutional shareholders reporting positions in this security for the Q2 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.